Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000395 · ClinicalTrials.gov registry record · Phase 2

Antifolate Effectiveness in Arthritis

A Phase 2 study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00000395: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.

NCT00000395 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000395, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.

Interventions

  • DRUG Methotrexate
  • DIETARY_SUPPLEMENT Folic acid
  • DIETARY_SUPPLEMENT Folinic acid

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1996-09
Est. Completion 2002-08
Phase Phase 2
University of Alabama at Birmingham

1,160 total trials

What the finished NCT00000395 record still lists

NCT00000395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 3 interventions - of which Methotrexate is the first listed.

NCT00000395 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000395 about?

NCT00000395 is a clinical study titled "Antifolate Effectiveness in Arthritis". This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by th...

What is the current status of trial NCT00000395?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1996-09. Estimated completion is 2002-08.

What interventions are being tested in trial NCT00000395?

The interventions under investigation include: Methotrexate (DRUG), Folic acid (DIETARY_SUPPLEMENT), Folinic acid (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00000395?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00000395's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00000395, the US trial registry maintained by the National Library of Medicine. NCT00000395 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.